icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated
 
 
  Reported by Jules Levin
EASL 2018 April 14 Paris France
Late Breaker oral
 
E Gane*1,2, A Liu3, MF Yuen4, C Schwabe2, Q Bo3, SK Das5, L Gao3, X Zhou3, Y Wang3, E Coakley6, Y Jin3 1. University of Auckland, 2. Auckland Clinical Studies, Auckland, New Zealand, 3. Roche Innovation Centre Shanghai, China, 4. Department of Medicine, The University of Hong Kong, Hong Kong, 5. Roche Products Ltd, Welwyn Garden City, United Kingdom, 6. Roche Innovation Centre New York, New York, United States 1

0418181

0418182

0418183

0418184

0418185

0418186

0418187